SARS-CoV-2 correlates of protection in a Latino-origin population

SARS-CoV-2 与拉丁裔人群的保护相关

• 批准号: 10706728
• 负责人: Marcos Lopez
• 金额: $ 40.71万
• 依托单位: UNIVERSITY OF PUERTO RICO MED SCIENCES
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-30 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10706728
• 关键词: 2019-nCoV; African; American; Antibodies; Antibody titer measurement; Autoimmune Diseases; Automobile Driving; Basic Science; Biological Assay; Black American; Black race; Blood Circulation; COVID-19; COVID-19 severity; COVID-19 susceptibility; COVID-19 test; COVID-19 vaccine; Clinical; Collaborations; Communicable Diseases; Data; Dengue; Detection; Development; Disease Outcome; Dissection; Enzyme-Linked Immunosorbent Assay; Epidemiology; Etiology; FDA Emergency Use Authorization; Future; Genetic; Goals; Health Policy; Healthcare Systems; Hispanic Populations; Immune; Immune response; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Immunologics; Immunophenotyping; Immunosuppression; Individual; Influenza; Institutional Review Boards; Integration Host Factors; Island; Knowledge; Laboratories; Latin American; Latino; Latino Population; Lead; Malignant Neoplasms; Methods; Modeling; Molecular; Mycoplasma; Obesity; Outcome; Patients; Pattern; Pharmaceutical Preparations; Phenotype; Play; Population; Predisposition; Prevalence; Privatization; Prognosis; Protocols documentation; Public Health; Puerto Rican; Puerto Rico; Research; Research Personnel; Respiratory syncytial virus; Risk; Role; SARS-CoV-2 antibody; SARS-CoV-2 infection; Sampling; Science; Serodiagnoses; Serology; Serology test; Seroprevalences; Severities; Social Environment; Source; Speech; T-Lymphocyte; Technology; Testing; Time; Trust; Uncertainty; Vaccines; Virus; Vulnerable Populations; Washington; World Health Organization; ZIKA; biobank; chikungunya; clinical diagnostics; cohort; comorbidity; cytokine; diagnostic platform; follow-up; interest; medically underserved; member; neutralizing antibody; news; novel coronavirus; pandemic disease; pathogen; programs; racial disparity; recruit; repository; severe COVID-19; social group; social vulnerability; socioeconomics; study population; transmission process; vaccine candidate; volunteer

The rapid global spread of SARS-CoV-2 has had a significant impact on the cancer population. SARSCoV-2 infection of hematopoietic stem cell transplant (HSCT) recipients leads to a poor prognosis with a ~68% survival rate. Immune mediated protection is critical to protect the HSCT population. However, there are significant gaps in our understanding of vaccine induced immune responses in the HSCT patient population. This proposed research will greatly advance our understanding of 1) mRNA vaccine driven immune responses in immune compromised subject populations, and 2) the functionality of the SARS-CoV-2 antigen specific T and B cell response in the HSCT population; 3) the role of the adaptive immune response in controlling breakthrough infections. The results of this proposal will have both short and long-term impacts. In the short term we will define a series of critical parameters that could improve the quality of life of HSCT patients during the pandemic. These studies will define the immunogenicity of mRNA SARS-CoV-2 vaccines before and after boosters. In two cohorts we will surveil for asymptomatic and symptomatic SARS-CoV-2 infections and evaluate the level of vaccine immunity close to the time of the breakthrough infection. In the long-term the SARS-CoV-2 pandemic was the 3rd global transmission of a novel coronavirus in the past 20 years. It is likely that there will be outbreaks in the future with currently unknown coronaviruses, and thus it is critical to determine now how high-risk groups respond to vaccination and if they require frequent booster vaccinations or potentially higher vaccine doses. Given the speed and efficacy of the mRNA vaccine platform, it is highly likely that the use of this vaccine platform will be expanded to combat other known pathogens, but also could be used to combat any range of potential emerging viral pathogens. The strength, breadth, and durability of responses to mRNA vaccines needs to be determined in different risk groups in longitudinal cohorts now, in order to prepare for future epidemics/pandemics.

SARS-COV-2的全球迅速蔓延对癌症人群产生了重大影响。 SARSCOV-2感染造血干细胞移植（HSCT）受体的感染导致预后不良，存活率约为68％。免疫介导的保护对于保护HSCT人群至关重要。但是，我们对HSCT患者人群中疫苗诱导的免疫反应的理解有很大的差距。这项提出的研究将大大提高我们对1）免疫受试者人群中mRNA疫苗驱动的免疫反应的理解，以及2）HSCT种群中SARS-COV-2抗原特异性T和B细胞反应的功能； 3）自适应免疫反应在控制突破感染中的作用。该提案的结果将产生短期和长期影响。在短期内，我们将定义一系列关键参数，这些参数可以改善大流行期间HSCT患者的生活质量。这些研究将定义助推器前后mRNA SARS-COV-2疫苗的免疫原性。在两个队列中，我们将监视无症状和有症状的SARS-COV-2感染，并评估接近突破感染时代的疫苗免疫水平。从长远来看，SARS-COV-2大流行是过去20年中新型冠状病毒的全球第三次传播。当前未知的冠状病毒可能会在未来发生爆发，因此现在必须确定高风险人群对疫苗接种的反应以及它们是否需要频繁的促进疫苗接种或潜在的疫苗剂量较高。鉴于mRNA疫苗平台的速度和功效，这种疫苗平台的使用很有可能会扩展以对抗其他已知的病原体，但也可以用于抵抗任何潜在的新兴病毒病原体。现在，需要在纵向人群的不同风险组中确定对mRNA疫苗反应的强度，广度和耐用性，以便为将来的流行病/流行病做准备。

项目成果

Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination.

• DOI: 10.3390/v13101972
• 发表时间: 2021-09-30
• 期刊: Viruses
• 作者: Sariol CAA;Pantoja P;Serrano-Collazo C;Rosa-Arocho T;Armina-Rodríguez A;Cruz L;Stone ETT;Arana T;Climent C;Latoni G;Atehortua D;Pabon-Carrero C;Pinto AKK;Brien JDD;Espino AMM
• 通讯作者: Espino AMM

Limited impact of Delta variant’s mutations in the effectiveness of neutralization conferred by natural infection or COVID-19 vaccines in a Latino population.

Delta 变体突变对拉丁裔人群中自然感染或 COVID-19 疫苗的中和效果影响有限。

• DOI: 10.1101/2021.10.25.21265422
• 发表时间: 2021
• 期刊: medRxiv : the preprint server for health sciences
• 作者: Sariol,CarlosA;Serrano-Collazo,Crisanta;Ortiz,EdwinJ;Pantoja,Petraleigh;Cruz,Lorna;Arana,Teresa;Atehortua,Dianne;Pabon-Carrero,Christina;Espino,AnaM
• 通讯作者: Espino,AnaM

Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination.

在追踪自然感染或 COVID-19 疫苗接种后对 SARS-CoV-2 刺突蛋白受体结合域的体液反应时，功能比数量更可靠。

• DOI: 10.1101/2021.06.02.21257975
• 发表时间: 2021
• 期刊: medRxiv : the preprint server for health sciences
• 作者: Sariol,CarlosA;Pantoja,Petraleigh;Serrano-Collazo,Crisanta;Rosa-Arocho,Tiffany;Armina,Albersy;Cruz,Lorna;Stone,ETaylor;Arana,Teresa;Climent,Consuelo;Latoni,Gerardo;Atehortua,Dianne;Pabon-Carrero,Christina;Pinto,AmeliaK;Brien,
• 通讯作者: Brien,

Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge.

• DOI: 10.3390/vaccines9080881
• 发表时间: 2021-08-09
• 期刊: Vaccines
• 影响因子: 7.8
• 作者: King RG;Silva-Sanchez A;Peel JN;Botta D;Dickson AM;Pinto AK;Meza-Perez S;Allie SR;Schultz MD;Liu M;Bradley JE;Qiu S;Yang G;Zhou F;Zumaquero E;Simpler TS;Mousseau B;Killian JT Jr;Dean B;Shang Q;Tipper JL;Risley CA;Harrod KS;Feng T;Lee Y;Shiberu B;Krishnan V;Peguillet I;Zhang J;Green TJ;Randall TD;Suschak JJ;Georges B;Brien JD;Lund FE;Roberts MS
• 通讯作者: Roberts MS